

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 July 2025 (24.07.2025)



(10) International Publication Number
WO 2025/155830 A1

(51) International Patent Classification:

C07D 471/04 (2006.01) A61P 25/00 (2006.01)
A61K 31/437 (2006.01) A61P 29/00 (2006.01)

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN,
WS, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2025/012047

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(22) International Filing Date:

17 January 2025 (17.01.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2024/072842

17 January 2024 (17.01.2024) CN

Published:

— with international search report (Art. 21(3))

(71) Applicants: **RAPPORT THERAPEUTICS, INC.**
[US/US]; 1325 Boylston Street, Suite 401, Boston,
MA 02215 (US). **JANSSEN PHARMACEUTICA NV**
[BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(71) Applicants: **KEANEY, Gregg, F.** [US/US]; 34 Robbins
Road, Lexington, MA 02421 (US). **XU, Jun** [CN/CN];
Biobay, 218 Xinghu Street, SIP, Room 101, Bldg. B4,
Suzhou, Jiangsu (CN). **Ji, Lingtao** [CN/CN]; Biobay, 218
Xinghu Street, SIP, Room 101, Bldg. B4, Suzhou, Jiangsu
(CN). **ZHAO, Xin** [CN/CN]; Biobay, 218 Xinghu Street,
SIP, Room 101, Bldg. B4, Suzhou, Jiangsu (CN). **FER-**
NANDES, Philippe [US/BE]; c/o Janssen Pharmaceuti-
ca NV, Turnhoutseweg 30, B-2340 Beerse (BE). **RYN-**
BERG, Raymond [US/BE]; c/o Janssen Pharmaceutica
NV, Turnhoutseweg 30, B-2340 Beerse (BE). **EHWE,**
Tracy [US/BE]; c/o Janssen Pharmaceutica NV, Turnhout-
seweg 30, B-2340 Beerse (BE). **NG, Alicia** [US/BE]; c/
o Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340
Beerse (BE).

(74) Agent: **DEGRAZIA, Michael, J.** et al.; McCarter & Eng-
lish, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

(54) Title: CRYSTALLINE FORMS OF 3-(7-CHLORO-1H-INDAZOL-5-YL)-2,5-BIS(TRIFLUOROMETHYL)-3H-IMIDA-
ZO[4,5-B]PYRIDINE AND THEIR USE IN THE TREATMENT OF EPILEPSY

(57) Abstract: Provided are crystalline forms of 3-(7-chloro-1H-indazol-5-yl)-2,5-bis(trifluoromethyl)-3H-imidazo[4,5-b]pyridine,
pharmaceutical compositions comprising the crystalline form, and their use in treating conditions associated with TARP γ 8-dependent
AMPA activity, such as epilepsy, epileptic disorders, seizures, seizure disorders, pain, psychiatric diseases, or neurodegenerative dis-
eases.

WO 2025/155830 A1